November 24, 2022 Non Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Third Quarter 2022
November 24, 2022 Non Regulatory Inbjudan till presentation av Promore Pharmas delårsrapport för Q3 2022
November 23, 2022 Regulatory Nomination Committee Appointed for the Annual General Meeting 2023 in Promore Pharma
November 1, 2022 Regulatory Promore Pharma provides an update on the Phase II clinical trial with ensereptide
August 23, 2022 Non Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the Second Quarter 2022
August 23, 2022 Non Regulatory Inbjudan till telefonkonferens om Promore Pharmas rapport för det andra kvartalet 2022
August 10, 2022 Non Regulatory Promore Pharma beviljas patent i Europa avseende behandling av kroniska sår
August 10, 2022 Non Regulatory Promore Pharma granted EU patent regarding treatment of chronic wounds
June 13, 2022 Regulatory The last clinic visit conducted in Promore Pharma’s phase II study of ensereptide
June 13, 2022 Regulatory Sista klinikbesöket genomfört i Promore Pharmas fas II-studie av ensereptide
May 17, 2022 Regulatory Report from the Annual General Meeting of Promore Pharma AB held on 17 May 2022
May 13, 2022 Non Regulatory Inbjudan till telefonkonferens om Promore Pharmas rapport för det första kvartalet 2022
May 13, 2022 Non Regulatory Invitation to Conference Call regarding Promore Pharma’s Interim Report for the First Quarter 2022
March 17, 2022 Regulatory Promore Pharma has reached recruitment goal in clinical trial of ensereptide
February 16, 2022 Regulatory Första patient rekryterad till Promore Pharmas kliniska prövning rörande ärrbildning enligt plan
February 16, 2022 Regulatory First patient recruited to Promore Pharma’s clinical trial regarding scarring according to plan
February 9, 2022 Non Regulatory Inbjudan till telefonkonferens med anledning av Promore Pharmas Bokslutskommuniké 2021
February 9, 2022 Non Regulatory Invitation to Conference Call regarding Promore Pharma’s Year-end Report 2021